J&J, Legend to Face Adcomm for Carvyktis Push as Earlier Line MM Treatment

The search results provided do not contain information about J&J, Legend, or their product Carvyktis in relation to an Adcomm (Advisory Committee) meeting for the treatment of early-line multiple myeloma (MM). The search results discuss other research topics, such as:

- Targeting multiple tumor-associated antigens by individual T cells
- Molecular mechanisms of HIV protease inhibitors against HPV-associated cervical cancer
- Implementation of the Southwestern Oncology Group Committee on clinical trials
- AACR Cancer Progress Report
- A light-activated antitumor platinum complex that kills human cancer cells

However, these topics are not directly related to the specific question about J&J, Legend, and Carvyktis.